Industry: Venture Capital
Annual Revenue Estimate: $0-$500,000
Email Convention: NA
Overall Ranking (NA)
The Overall Ranking is a score from 1 star (very bad) to 5 stars (excellent) generated based on the Company Reviews of current and former employees at this company, taking everything into account.
The number you see in the middle of the donut pie chart is the simple average of these scores. If you hover over the various sections of the donut, you will see the % breakdown of each score given.
The percentile score in the title is calculated across the entire Company Database and uses an adjusted score based on Bayesian Estimates (to account for companies that have few reviews). Simply put, as a company gets more reviews, the confidence of a "true score" increases so it is pulled closer to its simple average and away from the average of the entire dataset.
- 5 Stars
- 4 Stars
- 3 Stars
- 2 Stars
- 1 Star
To gain access to more statistics on this company and thousands of others including:1) % of interns receiving full time offers
2) The top undergraduate schools, majors and degrees this company targets
3) Interview stats breakdown on race, gender, military and sports data on the applicants,
Please click on the lock on the blue arrow and follow the instructions.
Want Access To These Statistics & Rankings?
- Free 1 month access by adding just 1 salary datapoint (here)
- REAL salary bonus data across 1,000+ companies
- Plus free 1 month access to 10,000+ interview insights
BioAdvance is an evergreen fund established to address the shortage of seed and pre-seed capital for companies developing new technologies to improve human health.
BioAdvance provides funding to startup life sciences companies in Southeastern Pennsylvania through its $20 million Greenhouse Fund. We invest in therapeutics, devices, diagnostics and platform technologies focused on human health.
Since its first investments in 2003, BioAdvance has become one of the nation's leading investors providing pre-seed and seed-stage funding. To date we have committed $19.9 million to 29 seed-stage companies and 19 pre-seed investments. Our portfolio companies are working to develop products to treat health problems including Alzheimer's disease, cancer, obesity, GI disorders, neurological and respiratory illnesses. BioAdvance investments have enabled its portfolio companies to leverage more than $1.4 billion in subsequent capital into the region (from private equity, grants, collaborations and M&A activity).
See in Google Maps
3701 Market Street, Philadelphia, PA, 19104, United States